Importance of tumor load in the sentinel node in melanoma: clinical dilemmas
- 22 June 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (8) , 446-454
Abstract
Sentinel lymph-node biopsy is an accurate staging procedure for patients with melanoma. However, this procedure followed by immediate completion lymph-node dissection (CLND) does not seem to improve survival, based on data from the MSLT-1 randomized trial. Patients with micrometastases <0.1 mm have a similar clinical course to sentinel-node-negative patients and routine CLND may not be indicated in these patients. The authors discuss the issue of prognostic false positivity and explain how the Rotterdam Criteria could be useful for the measurement of sentinel node tumor burden. There are two hypotheses to explain melanoma dissemination: first, simultaneous lymphatic and hematogeneous spread, with regional lymph nodes as indicators of metastatic disease; and second, orderly progression, with regional lymph nodes as governors of metastatic disease. The sentinel node (SN) has been defined as the first draining lymph node from a tumor and is harvested with the use of the triple technique and is processed by an extensive pathology protocol. The SN status is a strong prognostic factor for survival (83–94% for SN negative, 56–75% SN-positive patients). False-negative rates are considerable (9–21%). Preliminary results of the MSLT-1 trial did not demonstrate a survival benefit for the SN procedure, although a subgroup analysis indicates a possible benefit. A mathematical model has demonstrated 24% prognostic false positivity. SN tumor burden represents a heterogenous patient population and is classified most frequently with the Starz, Dewar or Rotterdam Criteria. A completion lymph-node dissection might not be indicated in all SN-positive patients. Patients classified with metastases <0.1 mm by the Rotterdam Criteria have excellent survival rates. Ultrasound-guided fine-needle aspiration cytology is emerging as a staging tool for high-risk patients, but more research is necessary before this can change clinical practice.Keywords
This publication has 87 references indexed in Scilit:
- Micrometastases or Isolated Tumor Cells and the Outcome of Breast CancerNew England Journal of Medicine, 2009
- Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodesCancer, 2009
- Importance of Sentinel Lymph Node Biopsy in Patients With Thin MelanomaArchives of Surgery, 2008
- The rationale for sentinel-node biopsy in primary melanomaNature Clinical Practice Oncology, 2008
- The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 casesBritish Journal of Cancer, 2008
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006
- Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)Annals of Surgical Oncology, 2000
- Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trialThe Lancet, 1998
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the LimbsNew England Journal of Medicine, 1977